L Van Bortel
Overview
Explore the profile of L Van Bortel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Faes C, Molenberghs G, Hens N, Van Bortel L, Vandeboel N, Pellens K, et al.
Vaccine X
. 2022 Jul;
11:100194.
PMID: 35855061
The vaccination coverage in Flanders is high, but some regions show lower vaccination willingness as compared to the overall vaccination coverage. Beginning November of 2021, the vaccination rate in Flanders...
2.
Katchunga P, Twagirumukiza M, Kluyskens Y, Kaishusha D, Baguma M, Bapolisi A, et al.
Rev Epidemiol Sante Publique
. 2015 Nov;
63(6):339-45.
PMID: 26586457
Background: Providing factual data about non-communicable diseases (NCDs) is of utmost importance in the sub-Saharan African countries where NCDs and arterial hypertension data remain scattered, scarce, and less representative given...
3.
Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, et al.
J Pharm Belg
. 2014 Sep;
(3):4-14.
PMID: 25226757
Background And Aim: Few well-designed randomized controlled trials (RCT) regarding the impact of community pharmacist interventions on pharmacotherapeutic monitoring of patients with Chronic Obstructive Pulmonary Disease [COPD) have been conducted....
4.
Kruse V, Somers A, Van Bortel L, De Both A, Van Belle S, Rottey S
J Clin Pharm Ther
. 2014 Jan;
39(3):259-65.
PMID: 24417304
What Is Known And Objective: Sunitinib, a CYP3A4 substrate, is standard of care treatment in metastatic renal cell carcinoma (mRCC) and is administered orally as a single dose of 50...
5.
Liu Y, Gu Y, Thijs L, Asayama K, Jin Y, Jacobs L, et al.
J Hum Hypertens
. 2013 Oct;
28(5):316-22.
PMID: 24152823
No longitudinal study addressed whether systolic blood pressure level (SBPL) or within-visit variability (SBPV) predict arterial properties or vice versa. In families randomly recruited from a Flemish population, we determined...
6.
Mehuys E, Dupond L, Petrovic M, Christiaens T, Van Bortel L, Adriaens E, et al.
J Nutr Health Aging
. 2012 Oct;
16(8):721-6.
PMID: 23076515
Objective: To describe medication management among home-dwelling older adults. These data should allow us to identify potential problems and to indicate target areas for community pharmacist intervention. Design: Cross-sectional observational...
7.
Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel L, Van Tongelen I, et al.
J Pharm Belg
. 2012 Sep;
(2):4-10.
PMID: 22978009
Aim: This observational community pharmacy-based study aimed to investigate headache characteristics and medication use of persons with regular headache presenting for self-medication. Methods: Participants (n=1205) completed ii) a questionnaire to...
8.
Azermai M, Petrovic M, Engelborghs S, Elseviers M, Van der Mussele S, Debruyne H, et al.
Aging Ment Health
. 2012 Aug;
17(1):125-32.
PMID: 22928861
Background: Antipsychotic use for behavioural and psychological symptoms of dementia (BPSD) is controversial. Guidelines advise to reduce antipsychotics given the adverse effects and limited efficacy, to limit dose and treatment...
9.
Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial
Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon J, et al.
J Clin Pharm Ther
. 2010 Dec;
36(5):602-13.
PMID: 21143256
What Is Known And Objective: There is little evidence from well-designed randomized controlled trials of the impact of community pharmacist intervention on the clinical management of patients with type 2...
10.
Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, et al.
Acta Clin Belg
. 2010 Dec;
65(5):300-4.
PMID: 21128555
Introduction: Trastuzumab (TRAS) is a humanised monoclonal antibody that is targeted against the HER2 growth factor receptor. Over-expression of the receptor occurs in around 15-25% of women with early breast...